Recent Developments, Liquidity and Management's Plans (Details Narrative) |
3 Months Ended | |||||
|---|---|---|---|---|---|---|
|
Apr. 16, 2021
USD ($)
$ / shares
shares
|
Apr. 16, 2021
USD ($)
$ / shares
shares
|
Nov. 11, 2020
USD ($)
|
Mar. 31, 2021
USD ($)
Integer
|
Mar. 31, 2020
USD ($)
|
Dec. 31, 2020
USD ($)
|
|
| Contribute an amount in cash | $ 569,366 | $ 18,617,955 | ||||
| Trade and other payables | 300,000 | 1,510,290 | ||||
| Research and development expenses | $ (19,365) | $ 2,483,057 | ||||
| Trading days | Integer | 10 | |||||
| Debt instrument, redemption, description | Milestone Shares to be issued be deemed to be less than $5.00 per share | |||||
| Debt instrument description | Bridge Loan Advances accrue interest at 5% per annum, which may be increased to 8% per annum upon occurrence of any event of default, from the date of such default. | |||||
| Secured Promissory Note [Member] | ||||||
| Advances to related party | $ 3,000,000 | $ 1,200,000 | ||||
| Premas Biotech PVT Ltd. [Member] | ||||||
| Repayments of related party debt | 1,200,000 | |||||
| Deferred cost | 300,000 | |||||
| Remaining balance of vaccine license and development costs | $ 10,290 | |||||
| Merger Agreement [Member] | MyMD Pharmaceuticals, Inc., [Member] | ||||||
| Accrued interest percentage | 5.00% | |||||
| Merger Agreement [Member] | MyMD Pharmaceuticals, Inc., [Member] | Maximum [Member] | ||||||
| Loans payable | $ 3,000,000 | |||||
| Subsequent Event [Member] | ||||||
| Description of contribution transaction | Cause Cystron to contribute substantially all of the assets associated with its business or developing and manufacturing Cystron's COVID-19 vaccine candidate to Oravax. In consideration for the Company's commitment to consummate the Contribution Transaction, Oravax issued to the Company 390,000 shares of its capital stock (equivalent to 13% of Oravax's outstanding capital stock on a fully diluted basis) and assumed all of the obligations or liabilities in respect of the assets of Cystron (excluding certain amounts due to Premas), including the obligations under the license agreement with Premas. In addition, Oravax agreed to pay future royalties to the Company equal to 2.5% of all net sales of products (or combination products) manufactured, tested, distributed and/or marketed by Oravax or its subsidiaries. | |||||
| Royalty payments to sellers, percentage | 0.025 | |||||
| Subsequent Event [Member] | MyMD Pharmaceuticals (Florida), Inc [Member] | ||||||
| Warrants to purchase | shares | 986,486 | 986,486 | ||||
| Option to purchase shares of common stock | shares | 4,188,315 | |||||
| Subsequent Event [Member] | Contribution Agreement [Member] | ||||||
| Contribute an amount in cash | $ 1,500,000 | $ 1,500,000 | ||||
| Contribute transaction of issuance of capital stock | shares | 390,000 | 390,000 | ||||
| Subsequent Event [Member] | Merger Agreement [Member] | ||||||
| Issuance of post reverse stock split | shares | 28,553,307 | |||||
| Exchange ratio percentage | 77.05% | |||||
| Agreement description | Upon completion of the Merger and the transactions contemplated in the Merger Agreement, the former stakeholders of MyMD Florida held approximately 77.39% of the Company's Common Stock outstanding on a fully diluted basis, assuming the exercise in full of the pre-funded warrants to purchase 986,486 shares of Company Common Stock and including 4,188,315 shares of Company Common Stock underlying options to purchase shares of MyMD Florida Common Stock assumed by the company at closing and after adjustments based on the Company's net cash at closing. Holders of pre-Merger common stock of the Company held approximately 22.95% of the outstanding equity of the Company. Also upon completion of the Merger and the transactions contemplated by the Merger Agreement, the Company assumed 4,188,315 MyMD Florida stock options subject to certain terms contained in the Merger Agreement (including, but not limited to, the amendment of such stock option to extend the term of such stock option for a period expiring on April 16, 2024, the second-year anniversary of the Merger (the "Option Exercise Period"). | |||||
| Option to purchase shares of common stock | shares | 4,188,315 | |||||
| Subsequent Event [Member] | Merger Agreement [Member] | Pre-funded Warrants [Member] | ||||||
| Warrants to purchase | shares | 986,486 | 986,486 | ||||
| Subsequent Event [Member] | Merger Agreement [Member] | MyMD Pharmaceuticals (Florida), Inc [Member] | ||||||
| Shares issued price per share | $ / shares | $ 0.7718 | $ 0.7718 | ||||
| Issuance of shares of potential milestone payments | shares | 28,553,307 | |||||